Graft-versus-Host Disease in Mini-transplant

References

• Slavin, S. and Seidel, H.J. (1982) "Hemopoietic activity in bone marrow chimeras prepared with total lymphoid irradiation (TLI)", Exp. Hematol., 10, 206–216.
   Web of Science ®Google Scholar
• Storb, R., Yu, C., Wagner, J.L., Deeg, H.J., Nash, R.A., Kiem, H.P., et al. (1997) "Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation", Blood, 89, 3048— 3054.
   Google Scholar
• Sharabi, Y., Abraham, V.S., Sykes, M. and Sachs, D.H. (1992) "Mixed allogeneic chimeras prepared by a non-myeloablative regimen: requirement for chimerism to maintain tolerance", Bone Marrow Transplant, 9, 191–197.
   PubMed Web of Science ®Google Scholar
• Stewart, F.M., Crittenden, R.B., Lowly, P.A., Pearson-White, S. and Quesenberry, P.J. (1993) "Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloab-lated mice", Blood, 81, 2566–2571.
   PubMed Web of Science ®Google Scholar
• Schiffmann, R., Medin, J.A., Ward, J.M., Stahl, S., Cottler-Fox, M. and Karlsson, S. (1995) "Transfer of the human glucocerebrosidase gene into hematopoietic stem cells of nonablated recipients: successful engraftment and long-term expression of the transgene", Blood, 86, 1218— 1227.
   Google Scholar
• Ricordi, C., Karatzas, T., Nery, J., Webb, M., Selvaggi, G., Fernandez, L., et al. (1997) "High-dose donor bone marrow infusions to enhance allograft survival: the effect of timing", Transplantation, 63, 7–11.
   PubMed Web of Science ®Google Scholar
• Fontes, P., Rao, A.S., Demetris, A.J., Zeevi, A., Trucco, M., Carroll, P., et al. (1994) "Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplanta-tion", Lancet, 344, 151–155.
   Google Scholar
• Giralt, S., Estey, E., Albitar, M., van Besien, K., Rondon, G., Anderlini, P., et al. (1997) "Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy", Blood, 89, 4531— 4536.
   Google Scholar
• Khouri, IF., Keating, M., Korbling, M., Przepiorka, D., Anderlini, P., O'Brien, S., et al. (1998) "Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemother-apy and allogeneic blood progenitor-cell transplantation as treat-ment for lymphoid malignancies", J. Clin. Oncol., 16, 28 17 — 2824.
   Google Scholar
• Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., et al. (1998) "Nonmyeloablative stem cell transplanta-tion and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases", Blood, 91, 756— 763.
   Google Scholar
• Weiden, P.L., Flournoy, N., Thomas, E.D., Prentice, R., Fefer, A., Buckner, C.D., et al. (1979) "Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts", N. Engl. J. Med., 300, 1068–1073.
   Google Scholar
• Weiden, P.L., Sullivan, K.M., Flournoy, N., Storb, R. and Thomas, E.D. (1981) "Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation", N. Engl. J. Med., 304, 1529 — 1533.
   Google Scholar
• Sullivan, K.M., Weiden, P.L., Storb, R., Witherspoon, R.P., Fefer, A., Fisher, L., et al. (1989) "Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia", Blood, 73, 1720— 1728.
   Google Scholar
• Horowitz, M.M., Gale, R.P., Sondel, P.M., Goldman, J.M., Kersey, J., Kolb, H.J., et al. (1990) "Graft-versus-leukemia reactions after bone marrow transplantation", Blood, 75, 555–562.
   Google Scholar
• Kolb, H.J., Schattenberg, A., Goldman, J.M., Hertenstein, B., Jacobsen, N., Arcese, W., et al. (1995) "Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia", Blood, 86, 2041–2050.
   Google Scholar
• Collins, R.H., Jr., Shpilberg, O., Drobyslci, W.R., Porter, D.L., Giralt, S., Champlin, R., et al. (1997) "Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation", J. Clin. Oncol., 15, 433–444.
   PubMed Web of Science ®Google Scholar
• Levine, J.E., Braun, T., Penza, S.L., Beatty, P., Cornetta, K., Martino, R., et al. (2002) "Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation", J. Clin. Oncol., 20, 405–412.
   Web of Science ®Google Scholar
• Childs, R., Chernoff, A., Contentin, N., Bahceci, E., Schrump, D., Leitman, S., et al. (2000) "Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation", N. Engl. J. Med., 343, 750 — 758.
   Google Scholar
• Childs, R., Clave, E., Contentin, N., Jayasekera, D., Hensel, N., Leitman, S., et al. (1999) "Engraftment kinetics after nonmyelo-ablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses", Blood, 94, 3234— 3241.
   Google Scholar
• Mineishi, S., Kanda, Y., Saito, T., Nakai, K., Malcimoto, A., Kami, M., et al. (2003) "Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies", Br. J. Haematol., 121, 296— 303.
   Web of Science ®Google Scholar
• Martino, R., Caballero, M.D., Simon, J.A., Canals, C., Solano, C., Urbano-Ispizua, A., et al. (2002) "Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell trans-plantation with reduced-intensity conditioning in acute myelogen-ous leukemia and myelodysplastic syndromes", Blood, 100, 2243 — 2245.
   Google Scholar
• Martino, R., Giralt, S., Caballero, M.D., Mackinnon, S., Corradini, P., Fernandez-Aviles, F., et al. (2003) "Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study", Haematologica, 88, 555–560.
   PubMed Web of Science ®Google Scholar
• Mohty, M., Bay, J.O., Faucher, C., Choufi, B., Bilger, K., Tournilhac, O., et al. (2003) "Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regi-men", Blood, 102, 470–476.
   Google Scholar
• Lee, C.K., Badros, A., Barlogie, B., Morris, C., Zangari, M., Fassas, A., et al. (2003) "Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning", Exp. Hematol., 31, 73–80.
   Web of Science ®Google Scholar
• Perez-Simon, J.A., Martino, R., Alegre, A., Tomas, J.F., De Leon, A., Caballero, D., et al. (2003) "Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation", Br. J. Haematol., 121, 104 — 108.
   Web of Science ®Google Scholar
• Ferrara, J.L. and Deeg, H.J. (1991) "Graft-versus-host disease", N. Engl. J. Med., 324, 667–674.
   Google Scholar
• Khouri, IF., Saliba, R.M., Giralt, S.A., Lee, M.S., Okoroji, G.J., Hagemeister, F.B., et al. (2001) "Nonablative allogeneic hemato-poietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality", Blood, 98, 3595–3599.
   Google Scholar
• McSweeney, P.A., Niederwieser, D., Shizuru, J.A., Sandmaier, B.M., Molina, A.J., Maloney, D. et al. (2001) "Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects", Blood, 97, 3390— 3400.
   Google Scholar
• Badros, A., Barlogie, B., Morris, C., Desikan, R., Martin, SR., Munshi, N., et al. (2001) "High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions", Blood, 97, 2574 — 2579.
   Google Scholar
• Branson, K., Chopra, R., Kottaridis, P.D., McQuaker, G., Parker, A., Schey, S., et al. (2002) "Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies", J. Clin. Oncol., 20, 4022 — 4031.
   Web of Science ®Google Scholar
• Perez-Simon, J.A., Kottaridis, P.D., Martino, R., Craddock, C., Caballero, D., Chopra, R., et al. (2002) "Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disor-ders", Blood, 100, 3121–3127.
   Google Scholar
• Kottaridis, P.D., Milligan, D.W., Chopra, R., Chakraverty, R.K., Chakrabarti, S., Robinson, S., et al. (2000) "In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation", Blood, 96, 2419 — 2425.
   Google Scholar
• Chakraverty, R., Peggs, K., Chopra, R., Milligan, D.W., Kottaridis, P.D., Verfuerth, S., et al. (2002) "Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen", Blood, 99, 1071 — 1078.
   Google Scholar
• Amrolia, P., Gaspar, H.B., Hassan, A., Webb, D., Jones, A., Sturt, N., et al. (2000) "Nonmyeloablative stem cell transplantation for congenital immunodeficiencies", Blood, 96, 1239 — 1246.
   Google Scholar
• Nakai, K., Mineishi, S., Kami, M., Saito, T., Hori, A., Kojima, R., et al. (2003) "Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution", Transplantation, 75, 2135–2143.
   Google Scholar
• Niederwieser, D., Mans, M., Sliizuru, J.A., Petersdorf, E., Hegenbart, U., Sandmaier, B.M., et al. (2003) "Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases", Blood, 101, 1620— 1629.
   Web of Science ®Google Scholar
• Wong, R., Giralt, S.A., Martin, T., Couriel, D.R., Anagnostopou-los, A., Hosing, C., et al. (2003) "Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treat-ment for myeloid malignancies in patients older than 55 years", Blood, 102, 3052— 3059.
   Google Scholar
• Mans, M.B., Niederwieser, D., Sandmaier, B.M., Storer, B., Stuart, M., Maloney, D., et al. (2003) "HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative condi-tioning for patients with hematologic malignancies", Blood, 102, 2021— 2030.
   Google Scholar
• Faulkner, R.D., Craddock, C., Byrne, J.L., Mahendra, P., Haynes, A.P., Prentice, H.G., et al. (2004) "BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoprolifera-tive diseases: GVHD, toxicity, and survival in 65 patients", Blood, 103, 428–434.
   Google Scholar
• Blaise, D., Bay, J.O., Faucher, C., Michallet, M., Boiron, J.M., Choufi, B., et al. (2004) "Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors", Blood, 103, 435–441.
   Google Scholar
• Ueno, N.T., Cheng, Y.C., Rondon, G., Tannir, N.M., Gajewslci, J.L., Couriel, D.R., et al. (2003) "Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors", Blood, 102, 3829 — 3836.
   Google Scholar
• Schetelig, J., Thiede, C., Bornhauser, M., Schwerdtfeger, R., Kiehl, M., Beyer, J., et al. (2003) "Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Coopera-tive German Transplant Study Group", J. Clin. Oncol., 21, 2747 — 2753.
   Web of Science ®Google Scholar
• Taussig, D.C., Davies, A.J., Cavenagh, J.D., Oakervee, H., Syndercombe-Court, D., Kelsey, S., et al. (2003) "Durable remissions of myelodysplastic syndrome and acute myeloid leuke-mia after reduced-intensity allografting", J. Clin. Oncol., 21, 3060 — 3065.
   Google Scholar
• Chan, G.W., Foss, F.M., Klein, A.K., Sprague, K. and Miller, K.B. (2003) "Reduced-intensity transplantation for patients with myelo-dysplastic syndrome achieves durable remission with less graft-versus-host disease", Biol. Blood Marrow Transplant, 9, 753–759.
   Web of Science ®Google Scholar
• Feinstein, L.C., Sandmaier, B.M., Hegenbart, U., McSweeney, P.A., Maloney, D.G., Gooley, T.A., et al. (2003) "Non-myelo-ablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission", Br. J. Haematol., 120, 281— 288.
   Web of Science ®Google Scholar
• Bertz, H., Potthoff, K. and Finke, J. (2003) "Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia", J. Clin. Oncol., 21, 1480–1484.
   Web of Science ®Google Scholar
• Einsele, H., Schafer, H.J., Hebart, H., Bader, P., Meisner, C., Plasswilm, L., et al. (2003) "Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning", Br. J. Haematol., 121, 411 — 418.
   Web of Science ®Google Scholar
• Or, R., Shapira, M.Y., Resnick, I., Amar, A., Ackerstein, A., Samuel, S., et al. (2003) "Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase", Blood, 101, 441–445.
   Google Scholar
• Sayer, H.G., Kroger, M., Beyer, J., Kiehl, M., Klein, S.A., Schaefer-Eckart, K., et al. (2003) "Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor", Bone Marrow Transplant, 31, 1089 — 1095.
   Google Scholar
• Robinson, S.P., Goldstone, A.H., Mackinnon, S., Carella, A., Russell, N., de Elvira, C.R., et al. (2002) "Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation", Blood, 100, 4310–4316.
   Google Scholar
• Kroger, N., Sayer, H.G., Schwerdtfeger, R., Kiehl, M., Nagler, A., Renges, H., et al. (2002) "Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality", Blood, 100, 3919— 3924.
   Google Scholar
• Giralt, S., Aleman, A., Anagnostopoulos, A., Weber, D., Khouri, I., Anderlini, P., et al. (2002) "Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma", Bone Marrow Transplant, 30, 367–373.
   PubMed Web of Science ®Google Scholar
• Parker, J.E., Shafi, T., Pagliuca, A., Mijovic, A., Devereux, S., Potter, M., et al. (2002) "Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens", Br. J. Haematol., 119, 144–154.
   Web of Science ®Google Scholar
• Rini, B.I., Zimmerman, T., Stadler, W.M., Gajewslci, T.F. and Vogelzang, N.J. (2002) "Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results", J. Clin. Oncol., 20, 2017–2024.
   Web of Science ®Google Scholar
• Bornhauser, M., Thiede, C., Platzbecker, U., Jenke, A., Helwig, A., Plettig, R., et al. (2001) "Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients", Clin. Cancer Res., 7, 2254–2262.
   Web of Science ®Google Scholar
• Bornhauser, M., Thiede, C., Schuler, U., Platzbecker, U., Freiberg-Richter, J., Helwig, A., etal. (2000) "Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin", Bone Marrow Transplant, 26, 119 —125.
   Google Scholar
• Giralt, S., Thai!, P.F., Khouri, I., Wang, X., Braunschweig, I., Ippolitti, C., et al. (2001) "Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation", Blood, 97, 631–637.
   PubMed Web of Science ®Google Scholar
• Martino, R., Caballero, M.D., Canals, C., Simon, J.A., Solano, C., Urbano-Ispizua, A., et al. (2001) "Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study", Br. J. Haematol., 115, 653–659.
   PubMed Web of Science ®Google Scholar
• Nagler, A., Aker, M., Or, R., Naparstek, E., Varadi, G., Brautbar, C., et al. (2001) "Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation", Exp. Hematol., 29, 362–370.
   Web of Science ®Google Scholar
• Nagler, A., Slavin, S., Varadi, G., Naparstek, E., Samuel, S. and Or, R. (2000) "Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma", Bone Marrow Transplant, 25, 1021— 1028.
   Google Scholar
• Mielcarek, M., Martin, P.J., Leisenring, W., Flowers, ME., Maloney, D.G., Sandmaier, B.M., et al. (2003) "Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation", Blood, 102, 756–762.
   Google Scholar
• Mattsson, J., Uzunel, M., Brune, M., Hentschke, P., Barkholt, L., Stierner, U., et al. (2001) "Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation", Br. J. Haematol., 115, 935–944.
   Web of Science ®Google Scholar
• Shlomchik, W.D., Couzens, M.S., Tang, C.B., McNiff, J., Robert, ME., Liu, J., et al. (1999) "Prevention of graft versus host disease by inactivation of host antigen-presenting cells", Science, 285, 412 — 415.
   Google Scholar
• Teshima, T., Ordemann, R., Reddy, P., Gagin, S., Liu, C., Cooke, KR., et al. (2002) "Acute graft-versus-host disease does not require alloantigen expression on host epithelium", Nat. Med., 8, 575–581.
   Web of Science ®Google Scholar
• Shlomchik, W.D. (2003) "Antigen presentation in graft-vs-host disease", Exp. Hematol., 31, 1187 — 1197.
   Web of Science ®Google Scholar
• Auffermann-Gretzinger, S., Lossos, IS., Vayntrub, TA., Leong, W., Grumet, F.C., Blume, KG., et al. (2002) "Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients", Blood, 99, 1442–1448.
   Google Scholar
• Mapara, MY., Kim, Y.M., Wang, S.P., Bronson, R., Sachs, D.H. and Sykes, M. (2002) "Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells", Blood, 100, 1903–1909.
   Google Scholar
• Mattsson, J., Uzunel, M., Remberger, M. and Ringden, O. (2001) "T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation", Transplantation, 71, 433–439.
   Google Scholar
• Niiya, H., Kanda, Y., Saito, T., Ohnishi, T., Kanai, S., Kawano, Y., et al. (2001) "Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludar-abine and busulfan", Haematologica, 86, 1071 — 1074.
   Google Scholar
• Mackinnon, S., Papadopoulos, E.B., Carabasi, M.H., Reich, L., Collins, N.H., Boulad, F., et al. (1995) "Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease", Blood, 86, 1261–1268.
   Google Scholar
• Giralt, S., Hester, J., Huh, Y., Hirsch-Ginsberg, C., Rondon, G., Seong, D., et al. (1995) "CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation", Blood, 86, 4337–4343.
   PubMed Web of Science ®Google Scholar
• Shimoni, A., Gajewski, J.A., Donato, M., Martin, T., O'Brien, S., Talpaz, M., et al. (2001) "Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation", Biol. Blood Marrow Transplant, 7, 568–575.
   PubMed Web of Science ®Google Scholar
• Ringden, O., Labopin, M., Gorin, N.C., Schmitz, N., Schaefer, U.W., Prentice, HG., et al. (2000) "Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia?", Br. J. Haematol., 111, 1130 — 1137.
   Web of Science ®Google Scholar
• Tsukada, N., Kobata, T., Aizawa, Y., Yagita, H. and Okumura, K. (1999) "Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation", Blood, 93, 2738–2747.
   Google Scholar
• Yang, Y.G., Qi, J., Wang, M.G. and Sykes, M. (2002) "Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells", Blood, 99, 4207 — 4215.
   Google Scholar
• Epperson, D.E., Margolis, D.A., McOlash, L., Janczak, T. and Barrett, A.J. (2001) "In vitro T-cell receptor V beta repertoire analysis may identify which T-cell V beta families mediate graft-versus-leukaemia and graft-versus-host responses after human leucocyte antigen-matched sibling stem cell transplantation", Br. J. Haematol., 114, 57–62.
   Web of Science ®Google Scholar
• Patterson, A.E. and Korngold, R. (2001) "Infusion of select leukemia-reactive TCR Vbeta + T cells provides graft-versus-leukemia responses with minimization of graft-versus-host disease following murine hematopoietic stem cell transplantation", Biol. Blood Marrow Transplant, 7, 187–196.
   Web of Science ®Google Scholar
• Clouthier, S.G., Cooke, KR., Teshima, T., Lowler, K.P., Liu, C., Connolly, K., et al. (2003) "Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect", Biol. Blood Marrow Transplant, 9, 592— 603.
   Web of Science ®Google Scholar
• Pan, L., Teshima, T., Hill, G.R., Bungard, D., Brinson, Y.S., Reddy, VS., et al. (1999) "Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforffi-dependent pathway while preventing graft-versus-host disease", Blood, 93, 4071–4078.
   Google Scholar
• Ringden, O., Hermans, J., Labopin, M., Apperley, J., Gorin, N.C. and Gratwohl, A. (1996) "The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT)", Leuk. Lymphoma, 24, 71 — 79.
   PubMed Web of Science ®Google Scholar